Literature DB >> 8018459

Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis.

L A Bauer1, T O'Sullivan, W G Reiss, J R Horn, K Opheim, D E Strandness, R L Carithers.   

Abstract

Duplex scanning was used to measure liver blood flow (hepatic artery and main branches of the portal and hepatic veins) in six healthy subjects, five cirrhotic patients, and six hepatitis patients. Antipyrine clearance and formation clearances to its metabolites were also measured. Compared with healthy control subjects, cirrhotic patients had a lower hepatic vein blood flow (-76%, P < 0.05). This was due primarily to a lower portal vein blood flow (-36%, NS). A statistically significant difference in liver blood flow between patients with hepatitis and normal subjects was not detected. Antipyrine half-life, clearance, and the area under the serum drug concentration vs time curve were significantly different in cirrhotic patients compared with the healthy subjects (mean +/- s.d.-healthy controls: t1/2 = 13.7 +/- 3.0 h, CL = 30.0 +/- 8.6 ml h-1 kg-1, AUC = 549 +/- 139 mg l-1 h; cirrhotic patients: t1/2 = 32.4 +/- 1.7 h, CL = 12.3 +/- 2.1 ml h-1 kg-1, AUC = 1061 +/- 218 mg l-1 h; P < 0.008). Antipyrine half-life, clearance, and the area under the serum drug concentration vs time curve were not significantly different in hepatitis patients compared with the healthy subjects (hepatitis patients: t1/2 = 14.3 +/- 3.7 h, CL = 29.3 +/- 8.5 ml h-1 kg-1, AUC = 498 +/- 142 mg l-1 h). The volume of distribution of antipyrine was similar in all three groups of subjects.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8018459      PMCID: PMC1364739          DOI: 10.1111/j.1365-2125.1994.tb04292.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  26 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data.

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1976-10

3.  The clearance of antipyrine and indocyanine green in normal subjects and in patients with chronic lever disease.

Authors:  R A Branch; J A James; A E Read
Journal:  Clin Pharmacol Ther       Date:  1976-07       Impact factor: 6.875

4.  Estimation of hepatic blood flow with indocyanine green.

Authors:  C M LEEVY; C L MENDENHALL; W LESKO; M M HOWARD
Journal:  J Clin Invest       Date:  1962-05       Impact factor: 14.808

5.  Transection of the oesophagus for bleeding oesophageal varices.

Authors:  R N Pugh; I M Murray-Lyon; J L Dawson; M C Pietroni; R Williams
Journal:  Br J Surg       Date:  1973-08       Impact factor: 6.939

6.  Clearance of antipyrine-dependence of quantitative liver function.

Authors:  P B Andreasen; L Ranek; B E Statland; N Tygstrup
Journal:  Eur J Clin Invest       Date:  1974-04       Impact factor: 4.686

7.  Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers.

Authors:  M Danhof; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1979-12       Impact factor: 4.335

8.  Mechanism for reduced drug clearance in patients with cirrhosis.

Authors:  D Pessayre; D Lebrec; V Descatoire; M Peignoux; J P Benhamou
Journal:  Gastroenterology       Date:  1978-03       Impact factor: 22.682

9.  Alterations in the disposition of differently cleared drugs in patients with cirrhosis.

Authors:  U Klotz; C Fischer; P Müller-Seydlitz; J Schulz; W A Müller
Journal:  Clin Pharmacol Ther       Date:  1979-08       Impact factor: 6.875

10.  Assay of antipyrine and its primary metabolites in plasma, saliva and urine by high-performance liquid chromatography and some preliminary results in man.

Authors:  M Danhof; E de Groot-van der Vis; D D Breimer
Journal:  Pharmacology       Date:  1979       Impact factor: 2.547

View more
  1 in total

Review 1.  Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update.

Authors:  D J Morgan; A J McLean
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.